Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

The increasing complexity of mercaptopurine pharmacogenomics.

Marsh S, Van Booven DJ.

Clin Pharmacol Ther. 2009 Feb;85(2):139-41. doi: 10.1038/clpt.2008.219. Review.

PMID:
19151640
2.

Recent advances in the pharmacogenomics of thiopurine methyltransferase.

Coulthard SA, Hall AG.

Pharmacogenomics J. 2001;1(4):254-61. Review.

PMID:
11908768
3.

Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia.

Dorababu P, Nagesh N, Linga VG, Gundeti S, Kutala VK, Reddanna P, Digumarti R.

Eur J Clin Pharmacol. 2012 Apr;68(4):379-87. doi: 10.1007/s00228-011-1133-1. Epub 2011 Oct 19.

PMID:
22009189
5.

Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment.

Uchiyama K, Nakamura M, Kubota T, Yamane T, Fujise K, Tajiri H.

J Gastroenterol. 2009;44(3):197-203. doi: 10.1007/s00535-008-2307-1. Epub 2009 Feb 13.

PMID:
19214663
6.

Clinical pharmacology and pharmacogenetics of thiopurines.

Sahasranaman S, Howard D, Roy S.

Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. doi: 10.1007/s00228-008-0478-6. Epub 2008 May 28. Review.

PMID:
18506437
7.

Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs.

Jung YS, Cheon JH, Park JJ, Moon CM, Kim ES, Lee JH, Kim SW, Kim JH, Hong SP, Kim TI, Kim WH.

J Hum Genet. 2010 Feb;55(2):121-3. doi: 10.1038/jhg.2009.125. Epub 2009 Dec 4.

PMID:
19960028
8.
9.

Cancer pharmacogenomics: SNPs, chips, and the individual patient.

McLeod HL, Yu J.

Cancer Invest. 2003;21(4):630-40. Review.

PMID:
14533451
10.

Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.

Karas-Kuzelicki N, Mlinaric-Rascan I.

Pharmacogenomics. 2009 Aug;10(8):1309-22. doi: 10.2217/pgs.09.78. Review.

PMID:
19663675
11.

Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia.

Dokmanovic L, Urosevic J, Janic D, Jovanovic N, Petrucev B, Tosic N, Pavlovic S.

Ther Drug Monit. 2006 Dec;28(6):800-6.

PMID:
17164697
12.

Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience.

van Aken J, Schmedders M, Feuerstein G, Kollek R.

Am J Pharmacogenomics. 2003;3(3):149-55. Review.

PMID:
12814323
13.

The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.

Tumer TB, Ulusoy G, Adali O, Sahin G, Gozdasoglu S, Arinç E.

Am J Hematol. 2007 Oct;82(10):906-10.

14.

Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2 - *24).

Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M.

Pharmacogenet Genomics. 2008 Oct;18(10):887-93. doi: 10.1097/FPC.0b013e3283097328.

PMID:
18708949
15.

Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics.

Salavaggione OE, Wang L, Wiepert M, Yee VC, Weinshilboum RM.

Pharmacogenet Genomics. 2005 Nov;15(11):801-15.

PMID:
16220112
16.

Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.

Wan Rosalina WR, Teh LK, Mohamad N, Nasir A, Yusoff R, Baba AA, Salleh MZ.

J Clin Pharm Ther. 2012 Apr;37(2):237-41. doi: 10.1111/j.1365-2710.2011.01272.x. Epub 2011 May 5.

PMID:
21545474
17.

TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients.

Kurzawski M, Dziewanowski K, Lener A, Drozdzik M.

Eur J Clin Pharmacol. 2009 May;65(5):533-40. doi: 10.1007/s00228-009-0630-y. Epub 2009 Feb 20.

PMID:
19229528
18.

Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.

Hawwa AF, Millership JS, Collier PS, Vandenbroeck K, McCarthy A, Dempsey S, Cairns C, Collins J, Rodgers C, McElnay JC.

Br J Clin Pharmacol. 2008 Oct;66(4):517-28. doi: 10.1111/j.1365-2125.2008.03248.x. Epub 2008 Jun 28.

19.

Clinical relevance of thiopurine S-methyltransferase gene polymorphisms.

Mladosievicova B, Dzurenkova A, Sufliarska S, Carter A.

Neoplasma. 2011;58(4):277-82. Review.

PMID:
21520983
20.

Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.

Weinshilboum RM.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):539-61. Epub 2006 Jun 29. Review.

PMID:
16807786

Supplemental Content

Support Center